Mithramycin A induces apoptosis by regulating the mTOR/Mcl-1/tBid pathway in androgen-independent prostate cancer cells

Journal of Clinical Biochemistry and Nutrition

Volumn 53, Issue 2, 2013, Pages 89-93

  Choi, Eun Sun ^a   Chung, Taeho ^b   Kim, Jun Sung ^c   Lee, Hakmo ^d   Kwon, Ki Han ^e   Cho, Nam Pyo ^a   Cho, Sung Dae ^a  

^a Chonbuk National University   (South Korea)

^b Joongbu University   (South Korea)

^c Biterials Co Ltd   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e Kwangju University   (South Korea)

Author keywords

Mithramycin A; MTOR; Myeloid cell leukemia 1; Prostate cancer; Truncated Bid

Indexed keywords

ANTINEOPLASTIC AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MITHRAMYCIN A; PROTEIN BID; PROTEIN MCL 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHOSPHORYLATION; PROSTATE CANCER; PROSTATE EPITHELIUM; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 84885138671     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.13-28     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Karnak D, Xu L. Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. CurrDrug Targets 2010; 11: 699-707.
3. Saraon P, Jarvi K, Diamandis EP. Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem 2011; 57: 1366-1375.
4. Assikis VJ, Simons JW. Novel therapeutic strategies for androgen-indepen-dent prostate cancer: An update. Semin Oncol 2004; 31 (2 Suppl 4): 26-32. (Pubitemid 38609790)
5. Lomb6 F, Menindez N, Salas JA, Mendez C. The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives. Appl Microbiol Biotechnol 2006; 73: 1-14. (Pubitemid 44627719)
6. Kofman S, Eisenstein R. Mithramycin in the Treatment of Disseminated Cancer. Cancer Chemother Rep 1963; 32: 77-96.
7. Zhang M, Mathur A, Zhang Y, et al. Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cells. Cancer Res 2012; 72: 4178-4192.
8. Malek A, Nufiez LE, Magistri M, et al. Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer. PLoS One 2012; 7: E35130.
9. Previdi S, Malek A, Albertini V, et al. Inhibition of Spl-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts. Gynecol Oncol 2010; 118: 182-188.
10. Venkov C, Plieth D, Ni T, et al. Transcriptional networks in epithelial-mes-enchymal transition. PLoS One 2011; 6: E25354.
11. Krajewski S, Bodrug S, Krajewska M, et al. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol 1995; 146: 1309-1319.
12. Kucukzeybek Y, Gul MK, Cengiz E, et al. Enhancement of docetaxel-in-duced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145. J Exp Clin Cancer Res 2008; 27: 37.
13. Aichberger KJ, Mayerhofer M, Gleixner KV, et al. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: Inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood 2007; 109: 3031-3041. (Pubitemid 46482104)
14. Lian J, Ni Z, Dai X, et al. Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation. Mol Cancer Ther 2012; 11: 416-426.
15. Choi ES, Jung JY, Lee JS, Park JH, Cho NP, Cho SD. Myeloid cell leukemia-1 is a key molecular target for mithramycin A-induced apoptosis in an-drogen-independent prostate cancer cells and a tumor xenograft animal model. Cancer Lett 2013; 328: 65-72.
16. Choi ES, Shim JH, Jung JY, et al. Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1. Cancer Sci 2011; 102: 742-748.
17. Jin HO, Hong SE, Woo SH, et al. Silencing of Twistl sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition. Cell Death Dis 2012; 3:e319.
18. Floc'h N, Kinkade CW, Kobayashi T, et al. Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res 2012; 72: 4483-4493.
19. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, et al. Targeting AKT/ mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008; 118: 3051-3064.
20. Gao H, Ouyang X, Banach-Petrosky WA, Shen MM, Abate-Shen C. Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. Cancer Res 2006; 66: 7929-7933. (Pubitemid 44299155)
21. Kremer CL, Klein RR, Mendelson J, et al. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006; 66: 1203-1212. (Pubitemid 44175342)
22. Cao C, Subhawong T, Albert JM, et al. Inhibition of mammalian target of ra-pamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 2006; 66: 10040-10047. (Pubitemid 44672057)
23. Ruggero D, Pandolfi PP. Does the ribosome translate cancer? Nat Rev Cancer 2003; 3: 179-192. (Pubitemid 37328870)
24. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945. (Pubitemid 39071573)
25. Pradelli LA, Beneteau M, Chauvin C, et al. Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation. Oncogene 2010; 29: 1641-1652.
26. Mills JR, Hippo Y, Robert F, et al. mTORCl promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA 2008; 105: 10853-10858.
27. Dai B, Kong YY, Ye DW, Ma CG, Zhou X, Yao XD. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int 2009; 104: 1009-1016.
28. Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotech-no/2011; 19: 940-945.
29. Sleiman SF, Berlin J, Basso M, Karuppagounder SS, Rohr J, Ratan RR. Histone deacetylase inhibitors and Mithramycin A impact a similar neuroprotective pathway at a crossroad between cancer and neurodegeneration. Pharmaceuticals (Basel) 2011; 4: 1183-1195.
30. Jia Z, Gao Y, Wang L, et al. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Spl degradation and synergistic antitumor activity. Cancer Res 2010; 70: 1111-1119.
31. Lee KA, Chae JI, Shim JH. Natural diterpenes from coffee, cafestol and kah-weol induce apoptosis through regulation of specificity protein 1 expression in human malignant pleural mesothelioma. J Biomed Sci 2012; 19: 60.
32. Shin JA, Jung JY, Ryu MH, Safe S, Cho SD. Mithramycin A inhibits my- eloid cell leukemia-1 to induce apoptosis in oral squamous cell carcinomas and tumor xenograft through activation of Bax and oligomerization. Mol Pharmacol 2013; 83: 33 - 41.
33. Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN. The role of mTOR in the management of solid tumors: An overview. Cancer Treat Rev 2009; 35: 148-159.
34. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
35. Campone M, Levy V, Bourbouloux E, et al. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer 2009; 100: 315-321.
36. Coloff JL, Macintyre AN, Nichols AG, et al. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res 2011; 71: 5204-5213.
37. Adams JM, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998; 281: 1322-1326. (Pubitemid 28406819)
38. Hikita H, Takehara T, Kodama T, et al. BH3-only protein bid participates in the Bcl-2 network in healthy liver cells. Hepatology 2009; 50: 1972-1980.
39. Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function. FEBS Lett 2010; 584: 2981-2989.
40. Clohessy JG, Zhuang J, de Boer J, Gil-G6mez G, Brady HJ. Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J Biol Chem 2006; 281: 5750-5759. (Pubitemid 43847674)